3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Multiple Myeloma
7
Lymphoma, Non-Hodgkin
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Recurrence
5
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
4
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Hematologic Neoplasms
3
Waldenstrom Macroglobulinemia
2
Plasmablastic Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma, Large B-Cell, Diffuse
2
Primary Myelofibrosis
1
Neoplasm, Residual
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hypergammaglobulinemia
1
Breast Neoplasms
1
Anemia, Aplastic
1
Interventions
blinatumomab
16
Cyclophosphamide
15
fludarabine phosphate
8
fludarabine
8
Methotrexate
7
Cytarabine
7
Rituximab
6
Vincristine
5
Mercaptopurine
5
Melphalan
4
Daunorubicin
4
obinutuzumab
3
Whole-Body Irradiation
3
Immunotherapy, Adoptive
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Doxorubicin
3
Dexamethasone
3
Asparaginase
3
tisagenlecleucel
2
thymoglobulin
2
pegaspargase
2
Vindesine
2
Thioguanine
2
Teniposide
2
Stem Cell Transplantation
2
Radiotherapy
2
Prednisone
2
Prednisolone
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
daratumumab
×
Lymphoid
×
Clear all
NCT07021677
2025-06-15
DARA_T_ALL
Tata Memorial Centre
Phase 2
Recruiting
18 enrolled